Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and for the month of July.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.
Epizyme Inc. (NASDAQ: EPZM) is expected to issue an update on its partial clinical hold of tazemetostat following reports of a child with advanced poorly differentiated chordoma, a rare bone cancer, developing a secondary T-cell lymphoma. Trial enrollment outside the United States has not been affected. Shares of Epizyme closed Friday at $13.55, in a 52-week range of $11.15 to $21.40 and with a consensus analyst target of $25.25.
Omeros Corp. (NASDAQ: OMER) is expected to release data from its Phase 2 study of OMS721/IgAN in patients not taking steroids (U.S. cohort). Shares of Omeros closed Friday at $18.14. The consensus analyst target is $36.40, and the 52-week range is $8.36 to $25.20.
Tesaro Inc. (NASDAQ: TSRO) is expected to issue an update on its regulatory discussions with FDA regarding niraparib in breast cancer. Shares of Omeros closed Friday at $44.47, with a consensus analyst target of $77.67 and a 52-week range of $38.40 to $143.45.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.
24/7 Wall St.The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.